Related Experiment Video
Updated: Sep 20, 2026
Pneumococcus Infection of Primary Human Endothelial Cells in Constant Flow
Published on: October 31, 2019
[Effect of pingyangmycin on the growth and cell cycle of human vascular endothelial cells]
Wei-dong Kong1, Yan-hao Li, Qing-le Zeng
1Department of Interventional Radiology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China. kongwd@msn.com
Objective:
To study the effect of pingyangmycin (PYM, bleomycin A5) on the proliferation and cell cycle of the cultured ECV304 cells, a human umbilical vein endothelial cell (HUVEC) line.
Methods:
The growth inhibition of PYM on ECV304 cells was measured by MTT assay and the changes in the cell cycle by flow cytometry.
Results:
After 10 microg/ml PYM treatment of the cells for 24, 48, and 72 h, the inhibition rates were 44.7%, 59.7%, and 74.4% respectively, showing a dose- and time-dependent inhibitory effect, with the 50% inhibitory concentration (IC50) of PYM corresponding to treatment durations of 24, 48 and 72 h being 32.94, 2.56 and 0.75 microg/ml respectively. Flow cytometry showed that ECV304 cell cycle was arrested at G2-M phase after 24-hour treatment with 1 microg/ml PYM, with significant reduction in the cell ratio of S phase and increase of G2-M phase (P<0.01)
Conclusion:
PYM can effectively inhibit the proliferation of ECV304 cells, the mechanism of which might involve the blocking of cell cycle.
Insights
Pingyangmycin (PYM) effectively inhibits human umbilical vein endothelial cell (HUVEC) proliferation in a dose- and time-dependent manner. This compound blocks cell cycle progression at the G2-M phase, suggesting a potential anti-proliferative mechanism.
Area of Science:
- Molecular Biology
- Cell Biology
- Pharmacology
Context:
- Human umbilical vein endothelial cells (HUVECs) are crucial in vascular biology.
- Understanding endothelial cell proliferation is vital for vascular research and therapeutics.
- Pingyangmycin (PYM), a form of bleomycin A5, is investigated for its biological effects.
Purpose:
- To investigate the anti-proliferative effects of Pingyangmycin (PYM) on cultured ECV304 cells, a human umbilical vein endothelial cell (HUVEC) line.
- To analyze the impact of PYM on the cell cycle progression of ECV304 cells.
Summary:
- MTT assays demonstrated a dose- and time-dependent inhibition of ECV304 cell growth by PYM, with significant effects observed at various time points.
- Flow cytometry revealed that PYM treatment leads to cell cycle arrest at the G2-M phase.
- A notable decrease in the S phase cell ratio and a significant increase in the G2-M phase ratio were observed post-treatment (P<0.01).
Impact:
- PYM exhibits potent inhibitory effects on ECV304 cell proliferation.
- The mechanism of PYM's action appears to involve the disruption of normal cell cycle progression.
- These findings suggest PYM as a potential agent for modulating endothelial cell behavior.
